The advantages of anti-hepatitis B virus drugs are: effectiveness, ease of use, and safety, but they also have the disadvantages of irregular course of treatment, susceptibility to viral resistance, and relapse after discontinuation. Lamivudine, adefovir, telbivudine, entecavir, tenofovir, clavudine, etc. Lamivudine (Herceptin) Advantages: longest time on the market, precise efficacy, few adverse effects, and access to health insurance; Disadvantages: low durable response rate, high viral resistance rate (14%, 38%, 49%, 66%). Adefovir (Haverix, Meizheng, Daidin, etc.) Advantages: low resistance mutation rate (0, 3%, 11%, 18%, 29%), still effective in lamivudine-resistant patients; Disadvantages: weak antiviral effect, slow onset of action, potential nephrotoxicity. Entecavir (Boludin) Advantages: strong action, low resistance rate (1.2% cumulative resistance rate at 5 years); Disadvantages: more expensive Tebivudine (Subivudine) Advantages: strong action, high HBeAg conversion rate (22%); Disadvantages: high mutation rate, side effects such as creatine kinase elevation, short time on the market, antiviral effect, long-term efficacy and safety are yet to be confirmed. Combination adefovir therapy is preferred for lamivudine-resistant patients, and alternating adefovir and switching to high-dose entecavir therapy is not recommended. Adefovir-resistant patients may be switched to or combined with tebivudine, lamivudine or entecavir. Clinical studies have shown that switching to interferon therapy in patients with nucleoside analogue resistance may be an effective treatment option.